Tìm theo
Palivizumab
Các tên gọi khác (2) :
  • anti-RSV
  • Synagis
antiviral agents
Thuốc Gốc
Biotech
CAS: 188039-54-5
ATC: J06BB16
ĐG : Abbott Laboratories Ltd. , http://www.abbott.com
Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF)
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Dược Lực Học : Synagis exhibits neutralizing and fusion-inhibitory activity against Respiratory syncytial virus (RSV). These activities inhibit RSV replication or spread. Synagis is given to prevent the development of lower respiratory tract disease in pediatric patients.
Cơ Chế Tác Dụng : Humanized monoclonal antibody (IgG1k) produced by recombinant DNA technology, directed to an epitope in the A antigenic site of the F protein of respiratory syncytial virus (RSV). Synagis is a composite of human (95%) and murine (5%) antibody sequences. The human heavy chain sequence was derived from the constant domains of human IgG1 and the variable framework regions of the VH genes Cor (1) and Cess (2). The human lightchain sequence was derived from the constant domain of Ck and the variable framework regions of the VL gene K104 withJk-4. Palivizumab is expressed from a stable murine (mouse) myeloma cell line (NS0). Palivizumab is composed of to heavy chains (50.6 kDa each) and two light chains (27.6 kDa each), contains 1-2% carbohydrate by weight and has a molecular weight of 147.7 kDa +/- 1 kDa (MALDI-TOF) Palivizumab binds to the fusion glycoprotein of RSV. This prevents its binding and uptake by host cellular receptors.
Dược Động Học :

▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system.
▧ Half Life :
18-20 days (in adults)
Chỉ Định : For prophylaxis of respiratory diseases casued by respiratory syncytial virus.
Liều Lượng & Cách Dùng : Powder, for solution - Intramuscular
Dữ Kiện Thương Mại
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00110
National Drug Code Directory
http://www.hipaaspace.com/Medical_Billing/Coding/National.Drug.Codes/PDF/60574-4114-1
PharmGKB
http://www.pharmgkb.org/drug/PA164748781
Wikipedia
http://en.wikipedia.org/wiki/Palivizumab
RxList
http://www.rxlist.com/cgi/generic2/palivizumab.htm
Drugs.com
http://www.drugs.com/cdi/palivizumab.html
... loading
... loading